Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

Vaccine Increases PFS for Metastatic Tumors

DOI: 10.1158/2159-8290.CD-NB2019-091 Published September 2019
  • Article
  • Info & Metrics
Loading

Researchers have speculated that adding vaccines to standard-of-care checkpoint-inhibitor monotherapy for some cancers might make treatment more potent. Now, a clinical trial suggests that the investigational personalized neoantigen vaccine NEO-PV-01 (Neon Therapeutics) boosts the effectiveness of the PD-1 inhibitor nivolumab (Opdivo; Bristol-Myers Squibb). The patients showed improvement over historical results for nivolumab alone.

As genome sequencing has become faster and less expensive, researchers have begun developing custom vaccines that target neoantigens specific to each patient's tumor. Cancer vaccines have a poor record as single agents—only one is FDA approved. However, personalized vaccines that target tumor-specific antigens are immunogenic in patients with melanoma, so they could synergize with checkpoint inhibitors.

To test this hypothesis, researchers enrolled 82 patients—34 with melanoma, 27 with smoking-associated non–small cell lung cancer (NSCLC), and 21 with bladder cancer—in a phase Ib trial. All patients had metastatic disease and received nivolumab while their vaccine was being manufactured and then concurrently with the vaccine, for a total of 2 years of treatment.

To create the personalized vaccine, researchers performed next-generation sequencing on DNA and RNA from each patient's tumor to identify neoantigens. Next, they analyzed the neoantigens to predict which ones were likely to stimulate an immune response. The scientists then incorporated peptides from the most promising candidates into a vaccine.

Manufacturing each patient's vaccine takes about 10 to 12 weeks from “needle to needle,” or from biopsy to the first injection, says Patrick Ott, MD, PhD, of Dana-Farber Cancer Institute in Boston, MA, a lead investigator for the trial.

The most recent top-line results from the trial, which the company released in July, showed that the vaccine caused side effects such as pain at the injection site and flu-like symptoms for 88.3% of patients. Two patients had side effects of grade 3 or higher after vaccination.

Analysis of tumor and blood samples from 12 patients with melanoma showed CD4+ and CD8+ T-cell responses to the neoantigens in the vaccine and tumor infiltration by T cells. The researchers also detected epitope spreading, a phenomenon in which T cells begin targeting neoantigens that aren't in the vaccine but that may be released by dying tumor cells. That finding suggests that the vaccine triggers destruction of tumor cells not only via neoantigen-specific T cells, but also by stimulating a broader range of T cells.

After a median of 13.4 months, the patients with melanoma had not reached their median progression-free survival (PFS), and 47% of them showed a response. Median PFS for the patients with NSCLC was 5.6 months, with a 22% response rate, and 5.6 months with a 24% response rate in patients with bladder cancer.

“The median PFS in all three tumor types is better than in historical controls,” notes Ott. For instance, two trials of nivolumab for metastatic melanoma reported median PFS of 3.1 and 6.9 months. The increased PFS could be a sign that “the vaccine is helping to generate immune responses that the PD-1 inhibitor can enhance,” Ott says.

“I think it's highly important,” says Cornelis Melief, MD, PhD, of Leiden University Medical Center and ISA Pharmaceuticals in the Netherlands, who wasn't connected to the research. The results demonstrate that “one can increase levels of T cells with a completely nontoxic and highly specific vaccine developed against neoantigens.”

Next year, Neon Therapeutics plans to launch a trial in patients with metastatic melanoma comparing the vaccine plus a checkpoint inhibitor to the checkpoint inhibitor alone. Melief says that researchers could also assess the vaccine by determining whether it restores responses in patients who are resistant to PD-1 monotherapy. “That would be a spectacular demonstration of the added value” of the vaccine. –Mitch Leslie

  • ©2019 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 9 (9)
September 2019
Volume 9, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Vaccine Increases PFS for Metastatic Tumors
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vaccine Increases PFS for Metastatic Tumors
Cancer Discov September 1 2019 (9) (9) OF1; DOI: 10.1158/2159-8290.CD-NB2019-091

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Vaccine Increases PFS for Metastatic Tumors
Cancer Discov September 1 2019 (9) (9) OF1; DOI: 10.1158/2159-8290.CD-NB2019-091
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Agios Exits Oncology
  • Congress Approves Increase in Cancer Funding
  • Tasmanian Devil Facial Tumor Disease Turns Endemic
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement